amitriptyline has been researched along with Disorders of Excessive Somnolence in 3 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This post-hoc analysis examined time to recovery in patients with acute, painful musculoskeletal conditions following cyclobenzaprine extended release (CER; AMRIX(®), Cephalon, Inc." | 7.77 | Time to recovery in patients with acute painful musculoskeletal conditions treated with extended-release or immediate-release cyclobenzaprine. ( Altman, CA; Landy, S; Xie, F, 2011) |
| "This post-hoc analysis examined time to recovery in patients with acute, painful musculoskeletal conditions following cyclobenzaprine extended release (CER; AMRIX(®), Cephalon, Inc." | 3.77 | Time to recovery in patients with acute painful musculoskeletal conditions treated with extended-release or immediate-release cyclobenzaprine. ( Altman, CA; Landy, S; Xie, F, 2011) |
| "A total of 73 patients with migraine headache with or without aura are included in this single-center, double-blind, randomized, and controlled trial." | 2.73 | A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. ( Aydinli, I; Keskinbora, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keskinbora, K | 1 |
| Aydinli, I | 1 |
| Landy, S | 1 |
| Altman, CA | 1 |
| Xie, F | 1 |
| Walker, M | 1 |
| Meekins, G | 1 |
| Hu, SC | 1 |
1 trial available for amitriptyline and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine.
Topics: Adult; Amitriptyline; Anticonvulsants; Antidepressive Agents, Tricyclic; Constipation; Disorders of | 2008 |
2 other studies available for amitriptyline and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Time to recovery in patients with acute painful musculoskeletal conditions treated with extended-release or immediate-release cyclobenzaprine.
Topics: Acute Disease; Administration, Oral; Adult; Amitriptyline; Delayed-Action Preparations; Disorders of | 2011 |
Yoga neuropathy. A snoozer.
Topics: Adult; Amitriptyline; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Disorders of Excessive S | 2005 |